Skip to main navigation Skip to search Skip to main content

A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Project: Research

Project Details

StatusFinished
Effective start/end date01/29/15 → 01/28/17

Funding

  • Vertex Pharmaceuticals Incorporated: $92,711.82